The saga over Corcept Therapeutics’s ($CORT) patent battles against prospective generics for Korlym® is approaching another stage. We previously discussed Teva’s ($TEVA) petition for post-grant review (PGR) of the ‘214 patent. Corcept has filed its preliminary response to Teva’s PGR, and the PTAB is scheduled to decide whether or not to institute the PGR by about November 23, 2019. The ‘214 patent is potentially the strong patent Corcept is currently wielding against generics, since it arguably does read upon Korlym®’s label. Now that the papers are in, what are the odds Teva’s PGR is instituted?
Read MoreCorcept Therapeutics ($CORT) recently filed a new lawsuit against Teva ($TEVA) related to Teva’s proposed generic for Korlym®. The new suit asserts three new patents that were recently listed in the Orange Book. Are the three new patents a game-changer?
Read MoreWe previously wrote about Corcept’s ($CORT) amended complaint in its Hatch-Waxman patent litigation against Teva ($TEVA) regarding Korlym®. On July 27, Teva filed another motion to dismiss. Corcept opposed the motion on August 21, and Teva filed its reply on August 28. The motion is now fully briefed. Who will prevail?
Read MoreEarlier this year, Teva ($TEVA) filed an ANDA to distribute a generic version of Korlym®, and soon thereafter, Corcept Therapeutics ($CORT) commenced a Hatch-Waxman patent suit in federal court in New Jersey. On June 15, 2018, Teva moved to dismiss the case. What is this motion all about? And will Teva’s motion prevail?
Read MoreCorcept Therapeutics recently received a Paragraph IV notice letter from Teva for its drug, Korlym®. The market’s reaction crushed the stock, sending it from approximately $23 to roughly $17 within a day. Corcept Therapeutics has essentially one drug, Korlym® (mifepristone). But whether Teva will enter with a generic version of Korlym® any time soon depends directly on the patents that Corcept has in its arsenal. What are those patents? Is the market’s reaction justified? Or is this a buying opportunity?
Read More